Detalles de la búsqueda
1.
Extended-release naltrexone/bupropion is safe and effective among subjects with type 2 diabetes already taking incretin agents: a post-hoc analysis of the LIGHT trial.
Int J Obes (Lond)
; 45(8): 1687-1695, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-34083744
2.
Association between weight-loss history and weight loss achieved in clinical obesity management: Retrospective chart review.
Obesity (Silver Spring)
; 30(10): 2071-2078, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-36150211
3.
An analysis of weight loss efforts and expectations in a Canadian Cohort: A retrospective medical chart review.
Clin Obes
; 11(3): e12449, 2021 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-33745235
4.
Sequential diets and weight loss: Including a low-carbohydrate high-fat diet with and without time-restricted feeding.
Nutrition
; 91-92: 111393, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34399399
5.
Real-world persistence with liraglutide 3.0 mg for weight management and the SaxendaCare® patient support program.
Obes Sci Pract
; 6(4): 382-389, 2020 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-32874673
6.
Weight loss and persistence with liraglutide 3.0 mg by obesity class in the real-world effectiveness study in Canada.
Obes Sci Pract
; 6(4): 439-444, 2020 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-32874678
7.
The effectiveness and safety of pharmaceuticals to manage excess weight post-bariatric surgery: a systematic literature review.
J Drug Assess
; 8(1): 184-191, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-33110683
8.
Liraglutide 3.0 mg for the management of insufficient weight loss or excessive weight regain post-bariatric surgery.
Clin Obes
; 9(4): e12323, 2019 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-31183988
Resultados
1 -
8
de 8
1
Próxima >
>>